Table 2.

Crude mortality rate and SMRs by country for COGHD group

Country	N	Follow-up years	Crude mortality (100,000 person-years) (95 % CI)	Observed deaths	Expected deaths	SMR (95 % CI)
Czech Republic	27	141.4	707.2 (17.9–3,940.4)	1	0.299	3.35 (0.08–18.64)
France	125	372.2	806.0 (166.2–2,355.6)	3	0.927	3.24 (0.67–9.46)
Germany	113	505.22	197.9 (5.0–1,102.8)	1	1.12	0.89 (0.02–4.97)
Netherlands	66	474.74	210.6 (5.3–1,173.6)	1	0.779	1.28 (0.03–7.15)
United Kingdom	40	160.81	1,865.5 (384.7–5,451.9)	3	0.278	10.81 (2.23–31.58)
United States	359	1,134.8	88.1 (2.2–491.0)	1	1.931	0.52 (0.01–2.89)
Overall	1,204	4,462.4	224.0 (107.5–412.1)	10	8.751	1.14 (0.55–2.10)

Mortality rate per 100,000 person-years = observed number of deaths × 100,000/total person-years. Expected number of deaths = sum of person-years × incidence rate for each age-gender group. Overall expected number of deaths = sum of expected deaths in each country. Overall observed number of deaths = sum of observed deaths in each country. Data for those countries without a death event are not depicted. However, the total person-years of follow-up and expected number of deaths are included in the overall estimate row. SMR = observed number of deaths/expected number of deaths. 95 % CI is the exact confidence interval based on Poisson distribution. Reference data sources for calculating expected cases: http://wonder.cdc.gov/ for US data and http://apps.who.int/ghodata/ for non-US data

CI confidence interval, COGHD group those patients with childhood-onset GH deficiency who received GH replacement during childhood and had available information on age, gender, and at least one follow-up visit, GH growth hormone, N number of patients, SMR standardized mortality ratio